Agent Capital

Carisma Therapeutics is a biotechnology company based in Philadelphia, Pennsylvania, focused on developing innovative cellular immunotherapies for the treatment of solid tumors. Founded in 2016, the company specializes in engineering chimeric antigen receptor (CAR) macrophages and monocytes, which are types of white blood cells that play a crucial role in the immune response. By harnessing advances in macrophage biology and adoptive cell transfer, Carisma aims to enhance cancer therapies, allowing for more effective treatment options for patients with solid tumors. The company is in the clinical stage of development, working to translate its proprietary technology into transformative therapies for various serious diseases.

Carbon Biosciences develops genetic medicines for the treatment of devastating diseases. They develop their vector using industrial-scale viral production platforms and can be used to deliver a wide-range of therapeutic modalities.

Vittoria Biotherapeutics develops gene-edited cell therapies. they provide next-generation, paradigm-shifting T-cell therapeutics that address unmet medical needs. Senza5 Technology from viTToria improves the efficacy, safety, and utility of cell-based treatments in preclinical settings.

Cyrus Biotechnology builds software tools to accelerate basic research in biotech, pharma, and industrial biotechnology. Cyrus Bench delivers an enterprise version of the Rosetta molecular modeling and design toolkit, with the associated array of bio-molecular computation tools. It was founded in 2014 and headquartered in Seattle, Washington.

Developer of antibody-based therapeutics intended to provide a new approach to treating fibrosis. The company engages in the development of therapeutics that target key fibrotic mediator proteins that aid in the development of fibrosis in chronically damaged organs, enabling medical practitioners to halt and reverse critical fibrosis and associated conditions.

Carisma Therapeutics is a biotechnology company based in Philadelphia, Pennsylvania, focused on developing innovative cellular immunotherapies for the treatment of solid tumors. Founded in 2016, the company specializes in engineering chimeric antigen receptor (CAR) macrophages and monocytes, which are types of white blood cells that play a crucial role in the immune response. By harnessing advances in macrophage biology and adoptive cell transfer, Carisma aims to enhance cancer therapies, allowing for more effective treatment options for patients with solid tumors. The company is in the clinical stage of development, working to translate its proprietary technology into transformative therapies for various serious diseases.

Carisma Therapeutics is a biotechnology company based in Philadelphia, Pennsylvania, focused on developing innovative cellular immunotherapies for the treatment of solid tumors. Founded in 2016, the company specializes in engineering chimeric antigen receptor (CAR) macrophages and monocytes, which are types of white blood cells that play a crucial role in the immune response. By harnessing advances in macrophage biology and adoptive cell transfer, Carisma aims to enhance cancer therapies, allowing for more effective treatment options for patients with solid tumors. The company is in the clinical stage of development, working to translate its proprietary technology into transformative therapies for various serious diseases.

Metagenomi, Inc. is a genetic medicines company based in Emeryville, California, focused on developing innovative gene editing systems for the treatment of genetic diseases. Since its incorporation in 2016, the company has utilized a proprietary metagenomics-derived genome editing toolbox that enables the creation of curative therapeutics. This toolbox encompasses a range of advanced technologies, including programmable nucleases, base editors, and various RNA and DNA-mediated integration systems, such as prime editing systems and CRISPR-associated transposases (CASTs). Metagenomi aims to address the challenges posed by diverse mutations that have traditionally been difficult to target with existing genome engineering approaches.

Palvella Therapeutics is a start-up life sciences company that focuses on relentlessly and selflessly serving abandoned patient populations with therapies. The company specializes in developing therapies that specifically target the root cause of the disease. Palvella Therapeutics was founded in 2015 and headquartered in Wayne, Pennsylvania.

Interius BioTherapeutics is a biopharmaceutical company that targets cancer. The company spun out the University of Pennsylvania and is targeting cancer.

ImCheck Therapeutics SAS is a biopharmaceutical company based in Marseille, France, founded in 2015. The company specializes in the development of immunotherapeutics aimed at addressing severe unmet medical needs, primarily in the field of immuno-oncology. ImCheck focuses on creating immuno-modulatory antibodies that target members of the butyrophilin super-family of checkpoint molecules, specifically engaging γ9δ2 T cells. Its research and development efforts are directed toward treating various cancers, including breast, gastric, and ovarian cancers, as well as other immune-related diseases. The company's innovative approach positions it at the forefront of next-generation immunotherapy solutions for patients suffering from solid tumors.

Metagenomi, Inc. is a genetic medicines company based in Emeryville, California, focused on developing innovative gene editing systems for the treatment of genetic diseases. Since its incorporation in 2016, the company has utilized a proprietary metagenomics-derived genome editing toolbox that enables the creation of curative therapeutics. This toolbox encompasses a range of advanced technologies, including programmable nucleases, base editors, and various RNA and DNA-mediated integration systems, such as prime editing systems and CRISPR-associated transposases (CASTs). Metagenomi aims to address the challenges posed by diverse mutations that have traditionally been difficult to target with existing genome engineering approaches.

Pyxis Oncology, Inc. is a biotechnology company focused on developing antibody therapeutics that enhance the immune response against cancer. Founded in 2018 and based in Boston, Massachusetts, the company specializes in analyzing tumor antigen-specific tumor-infiltrating lymphocytes within hot tumors and tumor cell signaling pathways in cold tumors. This research informs the creation of novel antibody-based immunotherapies aimed at targeting difficult-to-treat cancers. Pyxis Oncology's goal is to develop next-generation therapeutics that not only kill tumor cells but also address the underlying issues that facilitate cancer's proliferation and immune evasion, ultimately improving the quality of life for patients.

Entrada Therapeutics, Inc., a biotechnology company, engages in the treatment of diseases through the intracellular delivery of biologic. The company enables intracellular delivery of proteins, peptides, and nucleic acids and allows development of programs across intracellular target classes. Its Intracellular enzyme replacement therapy (IC-ERT) is a medical treatment that corrects an enzyme deficiency in the cell, Protein-Protein Interaction Inhibitors. The company was founded in 2016 and is based in Boston, Massachusetts.

Verge Genomics focuses on accelerating drug discovery for neurodegenerative diseases through the use of artificial intelligence and genomic data. The company has developed a platform that leverages machine learning to analyze large datasets, identifying genetic targets and predicting effective therapeutics. By mapping genes associated with various neurodegenerative conditions, Verge aims to discover drugs that can simultaneously target multiple genetic factors. Founded by experts in machine learning and neuroscience, Verge Genomics seeks to improve patient outcomes and reduce the costs associated with pharmaceutical development. The company is based in Mountain View, California, and has formed a strategic alliance with Datavant to enhance its data-driven approach.

Pliant Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in South San Francisco, California, specializing in the discovery and development of therapies for fibrotic diseases. The company's lead candidate, PLN-74809, is an oral small-molecule dual selective inhibitor of avß6 and avß1 integrins, currently being developed for idiopathic pulmonary fibrosis and primary sclerosing cholangitis. PLN-74809 has received Orphan Drug Designation from the U.S. Food and Drug Administration for both conditions and is undergoing Phase 2a trials for IPF, with plans for a Phase 2a trial in PSC. Pliant is also advancing PLN-1474, a small-molecule selective inhibitor of avß1, aimed at treating liver fibrosis associated with nonalcoholic steatohepatitis, which is in Phase 1 clinical trials and has a partnership with Novartis. In addition to these clinical efforts, Pliant has two preclinical programs targeting oncology and muscular dystrophies. Founded in 2015, Pliant Therapeutics is committed to addressing unmet medical needs in the field of fibrosis.

Carisma Therapeutics is a biotechnology company based in Philadelphia, Pennsylvania, focused on developing innovative cellular immunotherapies for the treatment of solid tumors. Founded in 2016, the company specializes in engineering chimeric antigen receptor (CAR) macrophages and monocytes, which are types of white blood cells that play a crucial role in the immune response. By harnessing advances in macrophage biology and adoptive cell transfer, Carisma aims to enhance cancer therapies, allowing for more effective treatment options for patients with solid tumors. The company is in the clinical stage of development, working to translate its proprietary technology into transformative therapies for various serious diseases.

Skyhawk Therapeutics is focused on the discovery and development of small molecule therapeutics aimed at correcting RNA expression. The company utilizes proprietary technology to design small molecules that specifically target binding pocket regions on RNA, ensuring both sequence and structural specificity during critical phases of RNA splicing. This innovative approach enables the development of therapies for various conditions, including cancer, neurological disorders, and rare diseases, particularly those associated with RNA mis-splicing known as exon skipping. Founded in 2015 and headquartered in Waltham, Massachusetts, Skyhawk Therapeutics was previously known as Rare Genetix before rebranding in 2018.

Orchard Therapeutics is a biopharmaceutical company based in London, focused on developing innovative gene therapies for serious and life-threatening rare diseases. Operating in the United Kingdom, European Union, and the United States, Orchard employs an autologous ex vivo gene therapy approach to transform patients’ hematopoietic stem cells into gene-modified products for treatment through a single administration. Its portfolio includes Strimvelis, the first approved gene therapy for adenosine deaminase-severe combined immunodeficiency (ADA-SCID), along with several products in clinical development targeting metachromatic leukodystrophy, Wiskott-Aldrich syndrome, X-linked chronic granulomatous disease, and transfusion-dependent beta-thalassemia. The company also has a robust preclinical pipeline addressing various mucopolysaccharidosis types. Orchard collaborates with leading institutions in gene therapy, enhancing its research capabilities and clinical programs. Founded in 2015, Orchard Therapeutics continues to demonstrate a commitment to transforming the lives of patients through its advanced therapies.

They at Orbus are committed to bringing innovative products to the extremely underserved patients affected by rare diseases. They are focused and passionate about bringing a more positive outcome to patients facing life-threatening or significantly life-altering diseases. Currently, Orbus Therapeutics is working to develop and commercialize eflornithine in North America. The company was founded in 2012 and is headquartered in Palo Alto, California.

Dragonfly Therapeutics, Inc. develops drugs to stimulate immune responses against cancer using its platform TriNKET. Dragonfly Therapeutics, Inc. has strategic collaborations with Celgene Corporation and Merck. The company was founded in 2015 and is based in Waltham, Massachusetts.